| Characteristic |
Value |
|
| Cancer stage (no. of patients)* |
|
| cT1 |
11 |
| cT2 |
35 |
| cT3 |
6 |
| pT2 |
2 |
| pT3 |
9 |
| No. of patients with symptoms or positive DRE results |
33 |
| No. of patients lost to follow-up |
5 |
| No. of patients with preexisting symptoms |
2 |
| No. of patients examined with endoscopy |
26 |
| Radiation dose (Gy) |
|
| Definitive radiation therapy (n = 51) |
|
| Median |
68.4 |
| Range |
66–70 |
| Postoperative radiation therapy (n = 11) |
|
| Median |
60 |
| Range |
60–66 |
| Prior to prostate brachytherapy boost (n = 1) |
45 |
| Follow-up (mo) |
|
| Median |
11.5 |
| Range |
1–53 |
| Latency of symptoms after radiation therapy (mo) |
|
| Median |
12 |
| Range |
2–39 |
|
| * The lowercase c refers to clinical staging; the lowercase p refers to pathologic staging. |
